2018 American Transplant Congress
Postoperative Immunological Profiles of Adult ABO-Incompatible Living Donor Liver Transplant Recipients
Background: Adult ABO-incompatible (ABOi) living donor liver transplantation has been performed for acute liver failure or end stage liver diseases when deceased liver allografts or…2018 American Transplant Congress
Impact of Preserved Collateral Veins on Small-for-Size Grafts in Living Donor Liver Transplantation
Center for Liver Cancer, National Cancer Center Research Institute, Goyang, Republic of Korea.
Purpose: Graft size is a critical issue in living donor liver transplantation (LDLT). We hypothesized that too much portal flow could possibly be diverted into…2018 American Transplant Congress
Liver Transplantation Post Gastric Bypass: Surgical Complications and Outcomes
Transplant Surgery, Medstar Georgetown Transplant Institute, Washington, DC.
Introduction: Liver transplantation in patients with prior gastric bypass poses a unique challenge and may increase the risk of complications.Aim: To characterize surgical complications in…2018 American Transplant Congress
Identifying Patients with CPRA>99.95% Likely to Be Offered Deceased Donor Kidneys
Emory Transplant Center, Atlanta, GA.
The implementation of the new kidney allocation system and priority of kidneys for cPRA=100% subjects revealed a hierarchy difference in allocation to patients with cPRA=99.45%-100%.…2018 American Transplant Congress
GDF15 Preventing Renal Ischemia Reperfusion Injury
1University of Western Ontario, London, ON, Canada; 2Jilin University, ChangChun, China.
Rationale: Ischemia reperfusion (I/R) injury still remains one of main causes of early renal dysfunction in kidney transplantation. There are no effective treatments for preventing…2018 American Transplant Congress
mTORC2 Deficiency in CD11c+ dendritic Cells Promotes Acute Kidney Injury
Introduction: The role of the mammalian/mechanistic target of rapamycin (mTOR) in the pathophysiology of renal ischemia-reperfusion injury (IRI) is poorly characterized; furthermore, the influence of…2018 American Transplant Congress
Five-Year Outcomes after Randomized Treatment by Rituximab in Early Acute Antibody-Mediated Rejection in Renal Transplantation: Long Term Outcomes of the RITUX ERAH Study
Background The place of rituximab in the treatment of acute antibody-mediated rejection (ABMR) is still controversial. The French multicenter double-blind, placebo-controlled RITUX ERAH study included…2018 American Transplant Congress
The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients
1Athena Study Group, Germany; 2Athena Study Group, France; 3Novartis, Pharma, Germany.
The ATHENA study was set up to compare efficacy and safety of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A [CyA] vs. a mycophenolic…2018 American Transplant Congress
Factors Related to Suboptimal Recovery of Renal Function after Living Donor Nephrectomy
Japanease Red Cross Kumamoto Hospital, Kidney Center, Kumamoto, Japan.
Introduction:Renal function of the living donor usually recovers to 60~70 percent of baseline function by compensatory hypertrophy mechanism. However, the degree of this compensatory hypertrophy…2018 American Transplant Congress
Opiate Use Trends after Liver Transplantation and the Factors Associated with Post-Transplant Opiate Dependence
1Henry Ford Hospital, Detroit, MI; 2Wayne State University SOM, Detroit, MI.
AimsOur study aims to determine predictive factors leading to post-liver transplant (LT) opioid dependence.MethodsA retrospective chart review was conducted including LT recipients from July 2013-June…
- 1
- 2
- 3
- …
- 211
- Next Page »